The effectiveness of tamsulosin in Benign Prostate Hyperplasia (BPH) patients with Lower Urinary Tract Symptoms (LUTS): a multi-centre cohort retrospective study

Ida Bagus Putra Pramana; Anak Agung Gede Oka; Gede Wirya Kusuma Duarsa; Kadek Budi Santosa; I Wayan Yudiana; Pande Made Wisnu Tirtayasa; Johan Renaldo; Lukman Hakim

doi:10.15562/ijbs.v14i1.214

The effectiveness of tamsulosin in Benign Prostate Hyperplasia (BPH) patients with Lower Urinary Tract Symptoms (LUTS): a multi-centre cohort retrospective study

Ida Bagus Putra Pramana ,

Anak Agung Gede Oka ,

Gede Wirya Kusuma Duarsa ,

Kadek Budi Santosa ,

I Wayan Yudiana ,

Pande Made Wisnu Tirtayasa ,

Johan Renaldo ,

Lukman Hakim ,

pdf |
DOI: https://doi.org/10.15562/ijbs.v14i1.214 |
Published: 2020-03-03

Abstract

Introduction: Lower urinary tract symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH) is a common condition in the ageing male. The first-line treatment of LUTS due to BPH is medical management with Î±-blockers or 5Î±-reductase inhibitors (5-ARIs). This study aims to analyze the effectiveness of tamsulosin to improve patients symptoms with LUTS due to BPH

Methods: A cohort retrospective study was conducted among 62 respondents with BPH at dr. Soetomo Hospital and Airlangga University Hospital from 2014-2016. The data collected related to characteristics of patients were age, prostate volume, Prostate-Specific Antigen (PSA), IPSS score, IPSS voiding score, IPSS storage score, IPSS quality of life, Qmax, voided volume and post voiding residual urine (PVR). All of the data were analyzed using SPSS version 17.0 for Windows.

Results: There were 62 samples with a mean age of 62.28 Â± 7.3 years old. The average prostate volume was 36.09 Â± 8.3 cc, and the PSA level was 2.8 Â± 1.45 ng/dl. Most of the respondents were in moderate LUTS criteria (54.8%). IPSS and Qmax score significantly improved in a comparison between pre-treatment, 1 month and 3 months after treatment (p<0.01). There was no adverse event or severe side effect reported.

Conclusion: Tamsulosin 0.4 mg daily resulted in statistically significant improvements of IPSS score, IPSS storage score, IPSS voiding score, IPSS Quality-of-life score, Qmax, Voided Volume and PVR through 1 month, but it also significantly improved IPSS score and uroflowmetry results in 3 months after treatment.

References

Roehrborn CG, Siami P, Barkin J, DamiÃ£o R, Major-Walker K, Nandy I, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123-31.
Miller J, Tarter TH. Combination Therapy with Dutasteride and Tamsulosin for the Treatment of symptomatic enlarged prostate. Clin Interv Aging. 2009;4:251-8.
Yuan JQ, Mao C, Wong SY, Yang ZY, Fu XH, Dai XY, et al. Comparative Effectiveness and Safety of Monodrug Therapies for Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia. A Network Meta-analysis. Medicine (Baltimore). 2015;94(27):e974
Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Viktrup L.. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel. placebo-controlled clinical trial. Eur Urol. 2012;61(5):917-25.
Thorne MB, Geraci SA. Acute urinary retention in elderly men. Am J Med 2009;122(9):815-9.
Jacobsen SJ, Girman CJ, Guess HA, Rhodes T, Oesterling JE, Lieber MM. atural history of prostatism: Longitudinal changes in voiding symptoms in community-dwelling men. J Urol. 1996;155(2):595â€“600.
Oh WK, Hurwitz M, D'Amico AV, et al. Neoplasms of the Prostate. In: Kufe DW, Pollock RE, Weichselbaum RR, et al., editors. Holland-Frei Cancer Medicine. 6th edition. Hamilton (ON): BC Decker; 2003. Chapter 111. Available from: https://www.ncbi.nlm.nih.gov/books/NBK13489/
Bruskewitz RC. Benign prostatic hyperplasia: drug and nondrug therapies. Geriatrics. 1992;47(12):39-42
Pradidarcheep W, Wallner C, Dabhoiwala NF, Lamers WH. Anatomy and histology of the lower urinary tract. Handb Exp Pharmacol. 2011;(202):117-48.